Bristol-Myers Squibb (NYSE:BMY) is KLCM Advisors Inc.’s 6th Largest Position

KLCM Advisors Inc. increased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 24.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 390,691 shares of the biopharmaceutical company’s stock after purchasing an additional 76,740 shares during the period. Bristol-Myers Squibb accounts for 3.1% of KLCM Advisors Inc.’s investment portfolio, making the stock its 6th largest holding. KLCM Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $20,046,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. OFI Invest Asset Management acquired a new position in shares of Bristol-Myers Squibb during the third quarter worth about $25,000. True Wealth Design LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $26,000. Milestone Investment Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the third quarter worth about $27,000. Coppell Advisory Solutions LLC purchased a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $28,000. Finally, Blue Bell Private Wealth Management LLC increased its position in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.5 %

NYSE:BMY traded down $0.25 during trading hours on Wednesday, hitting $48.26. 11,931,277 shares of the stock traded hands, compared to its average volume of 10,940,481. Bristol-Myers Squibb has a fifty-two week low of $47.58 and a fifty-two week high of $70.93. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The firm has a market cap of $97.81 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 1.46 and a beta of 0.39. The firm has a 50 day moving average price of $51.27 and a 200 day moving average price of $51.62.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. Bristol-Myers Squibb’s revenue for the quarter was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $1.82 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.97%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research analyst reports. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $61.12.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.